Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Accounts Payables (2022 - 2025)

Historic Accounts Payables for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $7.0 million.

  • Zentalis Pharmaceuticals' Accounts Payables fell 1427.7% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year decrease of 1427.7%. This contributed to the annual value of $7.4 million for FY2024, which is 5016.75% down from last year.
  • Per Zentalis Pharmaceuticals' latest filing, its Accounts Payables stood at $7.0 million for Q3 2025, which was down 1427.7% from $3.7 million recorded in Q2 2025.
  • Zentalis Pharmaceuticals' Accounts Payables' 5-year high stood at $20.4 million during Q2 2024, with a 5-year trough of $3.7 million in Q2 2025.
  • For the 4-year period, Zentalis Pharmaceuticals' Accounts Payables averaged around $11.0 million, with its median value being $11.2 million (2022).
  • As far as peak fluctuations go, Zentalis Pharmaceuticals' Accounts Payables soared by 6611.13% in 2024, and later plummeted by 8180.53% in 2025.
  • Over the past 4 years, Zentalis Pharmaceuticals' Accounts Payables (Quarter) stood at $11.2 million in 2022, then skyrocketed by 32.71% to $14.9 million in 2023, then crashed by 50.17% to $7.4 million in 2024, then fell by 5.47% to $7.0 million in 2025.
  • Its Accounts Payables stands at $7.0 million for Q3 2025, versus $3.7 million for Q2 2025 and $7.8 million for Q1 2025.